Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.neurologylive.com/view/ublituximab-outperforms-teriflunomide-cnm-au8-fails-healey-als-trial-benefits-aerobic-exercise-multiple-sclerosis
0
0
Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis - Neurology Live
+ 49 more
10/8/22 at 11:00am
Organization
Neurologylive.com
Author
NeurologyLive® Staff
Details
34 words
Summarize
Neurological Conditions
Health
Ublituximab Outperforms Teriflunomide
ARRS
CNM-Au8
HEALEY ALS Trial
Benefits of Aerobic Exercise
Multiple Sclerosis - Neurology Live Neurology News Network
Neurology News Network for the week ending October 8, 2022. [WATCH TIME: 3 minutes]
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...